Orig3n, a US-based developer of treatments for rare, inherited genetic diseases, raised $20m on Tuesday from investors including healthcare diagnostics company LabCorp and home care and nursing organisation Spectrum Health.
Hatteras Venture Partners led the round, which included Syno Capital, VC firm KTB’s KTB-Korus Fund, investment firm Mountain Group Partners’ MGC Venture Partners subsidiary, Defta Partners and 180 Degree Capital. Spectrum invested through its Spectrum Health Ventures subsidiary.
Founded in 2014, Orig3n uses DNA testing and personal contact with patients through networking events to develop personalised treatments that can repair tissue damage and disease. The funding will be used to push out Orig3n’s research efforts into cell therapy development.
The company closed a $12.5m series A round at the end of 2015 that also featured LabCorp, after it had secured $3.1m in February that year through a seed round backed by KTB, Harris & Harris, Defta and MGC.
Byron Smith, partner at Mountain Group Partners, joined Orig3n’s board of directors in conjunction with the round.